Amgen’s Bone Drug is Granted Two New Approvals

As reported by Pharma Times, Amgen’s new bone drug, Prolia has received two new indications by the US Food and Drug Administration:

  1. Prolia can how be used to help increase bone mass in women who are at high risk or fracture
  2. The drug has now been approved to increase bone mass in men at high risk of fracture who are receiving ADT for non-metastic prostate cancer.

The drug first received approval in the US in 2010  for the treatment of osteoporosis in post-menopausal women who are at high risk of fractures.

Are you looking for a new position in Drug Development? Click here to search our current roles online now.

Posted in: Industry News, News
CK Logo in place of featured image